Pirtobrutinib + Ibrutinib + Acalabrutinib + Zanubrutinib
Phase 3Active 0 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Lymphoma, Mantle-Cell
Conditions
Lymphoma, Mantle-Cell
Trial Timeline
Apr 8, 2021 → Apr 1, 2028
NCT ID
NCT04662255About Pirtobrutinib + Ibrutinib + Acalabrutinib + Zanubrutinib
Pirtobrutinib + Ibrutinib + Acalabrutinib + Zanubrutinib is a phase 3 stage product being developed by Eli Lilly for Lymphoma, Mantle-Cell. The current trial status is active. This product is registered under clinical trial identifier NCT04662255. Target conditions include Lymphoma, Mantle-Cell.
What happened to similar drugs?
18 of 20 similar drugs in Lymphoma, Mantle-Cell were approved
Approved (18) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
17
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04662255 | Phase 3 | Active |
Competing Products
20 competing products in Lymphoma, Mantle-Cell